ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMN ProMIS Neurosciences Inc

Trading 04-02 13:53:25 EDT

13.50

+0.50

+3.85%

High13.50	Low12.95	Vol7.03K
Open13.01	D1 Closing13.00	Amplitude4.19%
Mkt Cap121.06M	Tradable Cap13.77M	Total Shares8.97M
T/O92.33K	T/O Rate0.69%	Tradable Shares1.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMN","market":"US","secType":"STK","nameCN":"ProMIS Neurosciences Inc","latestPrice":13.5,"timestamp":1775152038313,"preClose":13,"halted":0,"volume":7025,"delay":0,"changeRate":0.038461538461538464,"floatShares":1019940,"shares":8967700,"eps":-22.61,"marketStatus":"Trading","change":0.5,"latestTime":"04-02 13:53:25 EDT","open":13.01,"high":13.5,"low":12.9547,"amount":92327.446425,"amplitude":0.041946,"askPrice":13.37,"askSize":200,"bidPrice":12.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-22.61,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775160000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":13,"preHourTrading":{"tag":"盘前","latestPrice":13.5,"preClose":13,"latestTime":"08:08 EDT","volume":30,"amount":405.06252,"timestamp":1775131736029,"change":0.5,"changeRate":0.038462,"amplitude":0.000769},"postHourTrading":{"tag":"盘后","latestPrice":13,"preClose":13,"latestTime":"18:51 EDT","volume":18,"amount":234.47,"timestamp":1775083893505,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.342},"requestUrl":"/m/hq/s/PMN","defaultTab":"news","newsList":[{"id":"2622875668","title":"ProMIS Neurosciences Inc  expected to post a loss of $1.91 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622875668","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622875668?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:22","pubTimestamp":1774624963,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc  expected to post a loss of $1.91 a share - Earnings Preview ProMIS Neurosciences Inc PMN.OQ PMN.O is expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F1H0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000666","title":"ProMIS Neurosciences Files $200 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000666","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000666?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:48","pubTimestamp":1774475323,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences  late Wednesday filed a shelf registration statement with US regulators for the potential sale of up to $200 million of securities, to be offered from time to time.The filing covers common shares, preferred shares, subscription receipts, debt securities, warrants and units.The company said it intends to use the net proceeds for the clinical development of PMN310 therapeutic candidate, for working capital and general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000314","title":"ProMIS Neurosciences files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000314?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:25","pubTimestamp":1774473926,"startTime":"0","endTime":"0","summary":"17:24 EDT ProMIS Neurosciences (PMN) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-files-200m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-files-200m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622719007","title":"ProMIS Neurosciences Inc - May Offer up to $50 Mln Common Shares Under Sales Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622719007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622719007?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:23","pubTimestamp":1774473813,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D11W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622073923","title":"ProMIS Neurosciences Q4 EPS $(21.83) Misses $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073923","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073923?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:05","pubTimestamp":1774440333,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(21.83) per share which missed the analyst consensus estimate of $(0.21) by 10295.24 percent. This is a 4266 percent decrease over losses of $(0.50) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51453181/promis-neurosciences-q4-eps-21-83-misses-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622626073","title":"ProMIS Neurosciences FY2025 net loss rises to $40 million; R&D expenses more than tripled to $33 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622626073","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622626073?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:03","pubTimestamp":1774440203,"startTime":"0","endTime":"0","summary":"FY2025 research and development expenses more than tripled to $33.4 million on higher costs to run the PRECISE-AD trial.FY2025 general and administrative expenses increased 9.68% to $6.8 million on higher employee headcount.Neil Warma said enrollment in the PRECISE-AD Phase 1b trial was completed in FY2025 and PMN310 had no treatment-related serious adverse events reported to date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLWhQjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4588","SG9999014021.USD","LU2095319765.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","SG9999014013.SGD","PMN","BK4139","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622946073","title":"ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622946073","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622946073?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440000,"startTime":"0","endTime":"0","summary":"PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in ear","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262145/0/en/ProMIS-Neurosciences-Announces-Full-Year-2025-Financial-Results-and-Provides-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","LU0757428866.USD","LU2125909916.SGD","BK4170","BK4595","LU1169589451.USD","BK4526","BK4143","BK4132","PMN","LU0053671581.USD","LU1169590202.USD","BK4181","LU1923622291.USD","LU2125909759.SGD","BK4023","BK4218","BK4600","LU0728928796.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620258030","title":"ProMIS Neurosciences to present ALS and Parkinson’s data at AD/PD 2026 conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258030","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258030?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:00","pubTimestamp":1773835249,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences to present ALS and Parkinson’s data at AD/PD 2026 conference               ProMIS Neurosciences will present two scientific posters at the AD/PD 2026 conference in Copenhagen, Den","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLc20HGz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP","BK4139","LU2210150020.SGD","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4112","NDAQ","SG9999014021.USD","SG9999014039.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","PMN","IE00BN0W2V16.EUR","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617242687","title":"ProMIS Neurosciences Director Eugene Williams Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617242687","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617242687?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:28","pubTimestamp":1772800108,"startTime":"0","endTime":"0","summary":"Eugene Williams, a director, reported an acquisition of 2,000 common shares of ProMIS Neurosciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL4P14pM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ProMIS Neurosciences Director Eugene Williams Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617567166","title":"ProMIS Neurosciences Director Eugene Williams Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617567166","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617567166?lang=en_us&edition=fundamental","pubTime":"2026-03-05 07:09","pubTimestamp":1772665745,"startTime":"0","endTime":"0","summary":"Eugene Williams, a director, reported the acquisition of common shares of ProMIS Neurosciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLbxh2vw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ProMIS Neurosciences Director Eugene Williams Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614591065","title":"ABG V-SIV IX Ltd Files Initial Beneficial Ownership Statement for ProMIS Neurosciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2614591065","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614591065?lang=en_us&edition=fundamental","pubTime":"2026-02-26 08:31","pubTimestamp":1772065862,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc. filed an initial statement of beneficial ownership naming ABG V-SIV IX Ltd as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL26hmG3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613782739","title":"ProMIS Chief Development Officer Johanne Kaplan Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782739","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782739?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:31","pubTimestamp":1771853496,"startTime":"0","endTime":"0","summary":"Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL2zQwHp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ProMIS Chief Development Officer Johanne Kaplan Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609592121","title":"ProMIS Neurosciences Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2609592121","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609592121?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:06","pubTimestamp":1770390360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2026 10:06 ET (15:06 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609535375","title":"ABG Management Ltd. Reports Acquisition of ProMIS Neurosciences Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609535375","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609535375?lang=en_us&edition=fundamental","pubTime":"2026-02-06 08:00","pubTimestamp":1770336040,"startTime":"0","endTime":"0","summary":"ABG Management Ltd. has reported the acquisition of common shares of ProMIS Neurosciences Inc. According to the filing, the transaction was conducted by ABG Management Ltd. and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL8w0J2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ABG Management Ltd. Reports Acquisition of ProMIS Neurosciences Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609318789","title":"ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609318789","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609318789?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:05","pubTimestamp":1770239100,"startTime":"0","endTime":"0","summary":"Cambridge, Massachusetts, Feb.  04, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s dise","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232486/0/en/ProMIS-Neurosciences-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","LU0053671581.USD","LU0757428866.USD","LU2211815571.USD","LU2125909759.SGD","BK4218","LU1923622291.USD","BK4023","BK4595","BK4170","LU2125909916.SGD","BK4132","BK4143","LU0728928796.USD","BK4211","LU1169589451.USD","BK4600","BK4181","BK4526","LU1815336091.USD","LU1169590202.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607044288","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:09 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2607044288","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607044288?lang=en_us&edition=fundamental","pubTime":"2026-01-30 23:09","pubTimestamp":1769785797,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:09 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nAQN2LK3H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607104142","title":"Promis Neurosciences Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2607104142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607104142?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:35","pubTimestamp":1769783731,"startTime":"0","endTime":"0","summary":"09:33 EST Promis Neurosciences (PMN) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607993043","title":"ProMIS Neurosciences : Proceeds Expected to Enable Completion of ProMIS' Landmark Phase 1B Ad Study and Support Execution of Key Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2607993043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607993043?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:02","pubTimestamp":1769778136,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nFWN3YV1JU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607189043","title":"ProMIS Neurosciences Inc: Extends Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2607189043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607189043?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:02","pubTimestamp":1769778136,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nFWN3YV1JU:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607704534","title":"ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704534","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607704534?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:00","pubTimestamp":1769778000,"startTime":"0","endTime":"0","summary":"Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones  Blinded 6-month top-line data expected mid-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/30/3229488/0/en/ProMIS-Neurosciences-Announces-Up-to-175-Million-Private-Placement-Financing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","BK4526","BK4595","BK4023","LU0728928796.USD","LU1923622291.USD","BK4600","PMN","BK4170","LU0053671581.USD","LU1169589451.USD","LU2125909759.SGD","LU2211815571.USD","BK4132","LU2125909916.SGD","LU1169590202.USD","LU0757428866.USD","BK4143"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.promisneurosciences.com","stockEarnings":[{"period":"1week","weight":-0.1798},{"period":"1month","weight":-0.4296},{"period":"3month","weight":0.9048},{"period":"6month","weight":0.0442},{"period":"1year","weight":-0.3112},{"period":"ytd","weight":0.9048}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0454},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0209},{"period":"1year","weight":0.168},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.492325},{"month":2,"riseRate":0.5,"avgChangeRate":0.1186},{"month":3,"riseRate":0,"avgChangeRate":-0.161081},{"month":4,"riseRate":0.75,"avgChangeRate":0.104553},{"month":5,"riseRate":0,"avgChangeRate":-0.176878},{"month":6,"riseRate":0,"avgChangeRate":-0.154013},{"month":7,"riseRate":0.333333,"avgChangeRate":0.096733},{"month":8,"riseRate":0,"avgChangeRate":-0.185569},{"month":9,"riseRate":0.5,"avgChangeRate":-0.048217},{"month":10,"riseRate":0.25,"avgChangeRate":-0.042317},{"month":11,"riseRate":0,"avgChangeRate":-0.242658},{"month":12,"riseRate":0.5,"avgChangeRate":-0.058437}],"exchange":"NASDAQ","name":"ProMIS Neurosciences Inc","nameEN":"ProMIS Neurosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProMIS Neurosciences Inc,PMN,ProMIS Neurosciences Inc股票,ProMIS Neurosciences Inc股票老虎,ProMIS Neurosciences Inc股票老虎国际,ProMIS Neurosciences Inc行情,ProMIS Neurosciences Inc股票行情,ProMIS Neurosciences Inc股价,ProMIS Neurosciences Inc股市,ProMIS Neurosciences Inc股票价格,ProMIS Neurosciences Inc股票交易,ProMIS Neurosciences Inc股票购买,ProMIS Neurosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction